Trends In Therapeutic Partnering
The
Trends in Therapeutic Partnering report provides the most comprehensive and
in-depth insight into the 35 most popular therapeutic targets for partnering in
the period 2007 to mid 2013.
To Read The Complete Report with
TOC:-
The
report provides a detailed understanding and analysis of the most popular
therapeutic targets for partnering in the period 2007 to mid 2013. The majority
of deals are discovery, preclinical and clinical stage whereby the licensee
obtains a right or an option right to license or access the licensors compounds
or product candidates. These deals tend to be multicomponent, starting with
collaborative R&D, and commercialization of outcomes.
One
of the key aspects of partnering is finding those companies that are potential
candidates for the development and commercialization of the next generation of
therapeutic targets. A lot of resources are spent on finding partners,
identifying their interests and making contact to initiate discussions.
Using
this report, dealmakers will effectively and efficiently target their
partnering activities to deliver the company’s business development objectives.
Over 300 charts allow quick understanding of therapeutic partnering trends
since 2007, together with insight into which companies are active in each of
the thirty five leading therapeutic areas.
Understanding
the flexibility of a prospective partner’s negotiated deals terms provides
critical insight into the negotiation process in terms of what you can expect
to achieve during the negotiation of terms. Whilst many smaller companies will
be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where
press releases and databases do not.
To Buy a Copy Of This Report:-
The
initial chapters of this report provide an orientation of therapeutic
dealmaking.
Chapter
1 provides an
introduction to the report, whilst
Chapter
2 provides an
overview of therapeutic dealmaking since 2007, listing the top therapeutic
areas for partnering by deal frequency and deal dollars committed by partnering
companies.
Chapter
3 reviews the top
pharma and biotech therapeutic partnering deals of 2007-2013 according to
reported deal size.
Chapter
4 provides a summary on best
practice on how to submit an opportunity to the leading therapeutic partnering
companies, to ensure building of relationships and to obtain a prompt
assessment and response from the business development function of the
prospective partner.
Chapter
5 lists forthcoming
partnering events where valuable face to face meetings with big biotech provide
a highly effective means of obtaining interest in novel opportunities. These
events are where dealmaking gets initiated through numerous back to back
meetings.
Contact:-
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment